Insmed Inc. diskutieren

Insmed

Buy                                                                                                                                                          

Gesundheit | Biotechnologie | Vereinigte Staaten

$

$

kyron7htx stimmt dem Sentiment von 'Sell' zu

klostergang stimmt der Sell-Einschätzung von kyron7htx zu

The open-label design of the Phase 3 trial will likely have a negative impact on secondary outcomes and may hinder the robustness of Insmed's NDA.

stratec stimmt der Outperform-Einschätzung der institutionellen Analysten zu

stratec stimmt am 09.06.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 38.44$ zu.

Insmed has a fairly strong product pipeline with Phase 2 and preclinical stage candidates. The company has strong chances of receiving approval for its ALIS therapy. (Amikacin Liposome Inhalation Suspension)

The drug is designed to treat nontuberculous mycobacterial (NTM),

a lung disease caused by Mycobacterium avium complex. What is even more encouraging is that the drug has been granted Priority Review status and its PDUFA date is set on September 28. The treatment has high probability of being accepted as it showed substantially higher success rate than current therapies for the ailment.

Insmed plans to launch the drug in the market by year-end.

klostergang stimmt der Outperform-Einschätzung der institutionellen Analysten zu